The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,516.00
Bid: 12,554.00
Ask: 12,556.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.016%)
Open: 12,500.00
High: 0.00
Low: 0.00
Prev. Close: 12,516.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Stabilisation Notice

19 Nov 2014 09:41

RNS Number : 4348X
Citigroup Global Markets Limited
19 November 2014
 



19th November 2014

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

 

AstraZeneca PLC

Stabilisation Notice

Citigroup Global Markets Limited. (contact: Syndicate Desk 0207 986 9000) hereby gives notice that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Regulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC).

 

The securities:

Issuer:

AstraZeneca PLC

Guarantor (if any):

Aggregate nominal amount:

€ TBC

Description:

Senior Unsecured REGS Only

Offer price:

TBC

Other offer terms

Stabilisation:

Stabilising Manager(s):

 Citigroup Global Markets Limited

 

Stabilisation period expected to start on:

19th November 2014

Stabilisation period expected to end no later than:

20th December 2014 (30 days after the proposed issue date of the securities)

Maximum size of over-allotment facility:

5% of the aggregate nominal amount stated above.

 

In connection with the offer of the above securities, the Stabilising Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilising Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

This announcement and the offer of the securities to which it relates are directed only at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STABLBLTMBIBMMI
Date   Source Headline
16th Mar 201711:00 amRNSNotice of AGM
15th Mar 20177:00 amRNSLYNPARZA PFS IN BRCA OVARIAN MAINTENANCE THERAPY
8th Mar 20177:00 amRNSFiling of Form 20-F with SEC
7th Mar 20172:30 pmRNSAnnual Financial Report
6th Mar 20177:00 amRNSDirectorate Change
3rd Mar 20177:00 amRNSALLIANCE WITH SANOFI PASTEUR FOR MEDI8897
1st Mar 20174:30 pmRNSTotal Voting Rights
28th Feb 20177:02 amRNSFDA approves once-daily Qtern for type-2 diabetes
24th Feb 201712:32 pmRNSCHMP positive opinion for ZS-9 in hyperkalaemia
20th Feb 20177:00 amRNSAZ licenses Zoladex to TerSera for the US & Canada
17th Feb 20177:00 amRNSLynparza positive in metastatic BRCA breast cancer
16th Feb 201712:01 pmRNSSILIQ (BRODALUMAB) APPROVED BY US FDA
2nd Feb 20177:00 amRNSAZN: FY16 and Q4 2016 Results
1st Feb 20174:00 pmRNSTotal Voting Rights
26th Jan 201710:00 amRNSSYMBICORT GRANTED PAEDIATRIC EXCLUSIVITY IN THE US
17th Jan 20177:00 amRNSAZ 1st-line lung cancer immuno-oncology programme
3rd Jan 20174:00 pmRNSTotal Voting Rights
23rd Dec 20167:00 amRNSAZ COMPLETES SALE OF ANTIBIOTICS BUSINESS
16th Dec 20161:00 pmRNSDirector/PDMR Shareholding
9th Dec 20163:05 pmRNSFDA accepts durvalumab for BLA in bladder cancer
6th Dec 20169:30 amRNSTagrisso data shows superiority over chemotherapy
5th Dec 20167:00 amRNSAZ completes agreement for Rhinocort Aqua rights
1st Dec 20164:00 pmRNSBlock listing Interim Review
1st Dec 20163:00 pmRNSTotal Voting Rights
22nd Nov 20167:00 amRNSAZ head and neck cancer trials resume enrolment
17th Nov 20167:00 amRNSAZ out-licensing deal with Allergan completed
10th Nov 20167:04 amRNSYear-To-Date and Q3 2016 Results
9th Nov 20167:00 amRNSDirectorate Change
1st Nov 20163:30 pmRNSDealing by Person Closely Associated
1st Nov 20163:00 pmRNSTotal Voting Rights
31st Oct 20161:47 pmRNSAZ completes US Aralez agreement for Toprol-XL
27th Oct 20164:51 pmRNSAstraZeneca Head and Neck Cancer Trials
26th Oct 20167:00 amRNSPositive results in AstraZeneca Lynparza trial
18th Oct 20167:00 amRNSFDA accepts for review ZS-9 NDA for hyperkalaemia
7th Oct 20167:00 amRNSAZ DIVESTS RIGHTS TO RHINOCORT AQUA OUTSIDE US
4th Oct 20167:05 amRNSAZ agreement with Aralez for Toprol-XL in US
4th Oct 20167:00 amRNSAstraZeneca reports top-line EUCLID results in PAD
3rd Oct 20163:00 pmRNSTotal Voting Rights
3rd Oct 20167:00 amRNSMedImmune out-licenses medicine to Allergan
28th Sep 20167:00 amRNSCHANGE TO ASTRAZENECA BOARD OF DIRECTORS
26th Sep 20164:00 pmRNSDirector/PDMR Shareholding
22nd Sep 201611:00 amRNSDirector Declaration
1st Sep 20162:30 pmRNSTotal Voting Rights
1st Sep 20167:00 amRNSAstraZeneca Completes Aspen Agreement
24th Aug 20167:00 amRNSAZ TO SELL ANTIBIOTICS BUSINESS TO PFIZER
18th Aug 20161:00 pmRNSDirector Declaration
16th Aug 20167:00 amRNSAstraZeneca completes agreement with LEO Pharma
10th Aug 20162:41 pmRNSASTRAZENECA ANNOUNCES INVESTMENT IN MODERNA
9th Aug 20167:00 amRNSASTRAZENECA UPDATE ON SELUMETINIB PHASE III TRIAL
1st Aug 20162:30 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.